Rɪᴏʏᴇ Aᴜꜱᴋ
@Polarbear900R
Academic read of the day! Crossover in oncology? A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by @AlysonHaslam & @VPrasadMDMPH in @Annals_Oncology Seminal 2018 paper and still as relevant! ➡️bit.ly/3TZCOUc
Sequential vs Induction Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma @JAMAOnc jamanetwork.com/journals/jamao…
🔹FLAURA2 confirms it: Osimertinib + chemo sets a new OS record (50.0 vs 42.1 mo, HR 0.75). But does this kill sequential strategy? Not necessarily. Post-progression Amivantamab still matters perhaps even more after earlier TKI + chemo pressure. 🔗 bit.ly/FLAURA2-OS #EGFR
Two powerful perspectives. One critical decision. In this high-stakes debate @tnewsomdavis defends osimertinib, while @LeXiuning makes the case for amivantamab + lazertinib. What’s the smarter frontline strategy in EGFR+ metastatic NSCLC? Join the ILCS on 26ᵗʰ September & decide
I’m happy to share our latest work on tumour necrosis! During my time in the @megeblad lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13) nature.com/articles/s4158…
HUTCHMED $HCM announces that the #NDA for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) has been granted approval by 🇨🇳 #NMPA for the treatment of patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET…
FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…
🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️@AstraZeneca @OncoAlert @Larvol #EGFR @EGFRResisters astrazeneca.com/media-centre/p…
PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as 1st-line Treatment in Pts with EGFRm Advanced NSCLC (FLAURA2) by Prof. Pasi Janne. Very important but huge space open for discussion. We need mature PFS2 and OS to discuss with pts. #LCSM #WCLC23 @IASLC @OncoAlert
Big win for lung cancer treatment! Tagrisso + chemo = significant OS benefit in EGFRm advanced NSCLC. 🌍 Approved in 80+ countries 💊 Longest PFS in this setting 🔬 Game-changing results from the FLAURA2 trial! pharmafocusamerica.com/pharma-exclusi… #Tagrisso #NSCLC #EGFR #FLAURA2 #Oncology
Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer. Learn more about FLAURA2 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #Oncology #ClinicalTrials #CancerData…
Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer astrazeneca.com/media-centre/p…
Undruggable ‘disordered’ proteins become druggable with new AI techniques from David Baker. @ScienceMagazine science.org/doi/10.1126/sc…
At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled
Adjuvant therapy in pStage IA1–IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study) - @LungCaJournal lungcancerjournal.info/article/S0169-…
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer jnj.com/media-center/p…
New 5-year data from #IMpower010 @JCO_ASCO ☑️PD-L1 ≥50%: Strongest benefit – recommend adjuvant atezolizumab. ☑️PD-L1 ≥1%: Meaningful DFS benefit, trending OS benefit – atezo is supported. ☑️PD-L1 negative/unknown: No proven benefit – not routinely recommended.…
origAMI1: effect of Amivantamab in previously treated Ras wild ca colon: encouraging outcomes in patients with a good prior response to EGFRi and longer time since prior EGFRi therapy @myESMO
🧬 NEW ASCO 2025 (driver+) NSCLC guideline updates key first-line strategies: ✅ EGFR: Osimertinib ✅ ALK: Alectinib or Lorlatinib ❌ Brigatinib removed 🎯 KRAS G12C: Sotorasib/Adagrasib post-CT 🧠 CNS efficacy + tolerability prioritized 📄 ascopubs.org/doi/10.1200/JC… #LungCancer
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management - Borgeaud - CA: A Cancer Journal for Clinicians - Wiley Online Library acsjournals.onlinelibrary.wiley.com/doi/full/10.33…
Pan-cancer human brain metastases atlas at single-cell resolution dlvr.it/TLw4ZN